Sector News

Latest News: Life sciences

March 15, 2024
Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024
Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024
Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

March 10, 2024
Life sciences

The approval is for the drug’s use in combination with Roche’s Gazyva (obinutuzumab). Adults with relapsed or refractory forms of the cancer who have tried two or more lines of systemic therapy will be eligible for the combination therapy.

March 10, 2024
Life sciences

UCB of Belgium and CDMO Samsung Biologics of South Korea have expanded their seven-year partnership with a new drug substance manufacturing deal worth 382 billion Korean won ($288 million). Among the drugs Samsung will manufacture for UCB is an anti-Tau candidate to treat progressive supranuclear palsy (PSP), which is in early-stage testing.

Subscribe to our Weekly Newsletter

We're easy to reach

How can we help you?

We're easy to reach